CYSTEAMINE ISOBIONIC-AMIDE: Potentiating Effects on Pigment Correction

PIGMENT CORRECTION

Dr Behrooz Kasraee, MD
Dermatologist, Dir. Swiss Vitiligo Center
Chief Scientific Officer, Scientis SA

Date: 25.09.2025
Courtesy of Dr Chau Yee Ng (Taiwan)

Liu RT, Tsai T, Lai Y, Ng, CY. Efficacy and safety of cysteamine-isobionicamide complex in postinflammatory hyperpigmentation: A 16-week, randomized, double-blinded, vehicle-controlled trial. *Dermatologica Sinica*.2023;41(4)222-230.

Cyspera®

The Pigmentation Authority

1966

Prof. Fitzpatrick's discovery of Cysteamine and superior efficacy to hydroquinone in vivo.

2010

Cysteamine, the First Physiologic Pigment Corrector



2022

Isobionic-Amide, the Next-Generation InflammAging Repair Active



2026

Oral TyroCutin, The First Oral Tyrosinase Inhibitor

20+	8	20+	40+
YEARS of RESEARCH	PATENTS	INTERNATIONAL PUBLICATIONS	INTERNATIONAL CLINICAL STUDIES

cyspera®
PIGMENT CORRECTION

WHY THE NEED: Powerful and well-tolerated



Cysteamine Isobionic-Amide Depigmenting Complex provides **superior benefits in pigmentation:**

- ✓ **"Pigmentation disorders are psychologically devastating"** (1). Patients seek non-visible (no downtime) treatments which are safe for long-term use
- ✓ Clinicians seek effective **non-mutagenic, non-carcinogenic** agents which do not carry risk of chemical vitiligo
- ✓ **The Safety of hydroquinone** is an area of significant debate despite status as the gold standard to reduce hyperpigmentation[2]
  - ✓ Reputation as a *potentially mutagenic and carcinogenic compound known to induce ochronosis[3]
  - ✓ HQ combinations can lead to irritation and phototoxic reactions
- ✓ Non-hydroquinone topical agents such as tranexamic acid, kojic acid, arbutin, azelaic acid, retinoids, hydroxy acids have shown lower efficacy. All are generics.

Note: size represent notoriety of Active ingredient

(1) Pearl Grimes, MD FAAD

(2) Westerhof et al. Hydroquinone and its analogues in dermatology - a potential health risk. J Cosm. Derm. 2005:4(2):55-9.

(3) Miles and Wilkerson, The dark side of hydroquinone for skin lightening: 3-fold increased risk of skin cancer.J Investigative Derm. 2022:5.936.

scientis THE PIGMENTATION AUTHORITY

INTENSIVE Pigment Correction

for moderate to severe pigmentation concerns



INTENSIVE

Cysteamine 7%
Isobionic-Amide 3.5%

30ml, USD 150

5-15 min. Rince-Off mask application

or

ORIGINAL+

Cysteamine 5%
Isobionic-Amide 5%

30ml, USD 140

3-5 min. Rince-Off mask application

SENSITIVE Pigment Correction

for sensitive skin and intimate area

X

INTENSIVE DUO, USD 205

SENSITIVE DUO, USD 195

epidermal regeneration for
INFLAMAGING
and **Photo-aging**
Dyschromia



BOOST

Isobionic-Amide 5%

30ml, USD 110.-

Leave-on cream application

scientis
THE PIGMENTATION AUTHORITY

What is **Cysteamine**?

More than 50 years ago, cysteamine was shown to be significantly more effective than hydroquinone *in vivo*

In 1966, Prof. Chavin discovered the physiologic activity of cysteamine in skin pigmentation, while studying black goldfish models.

In 1968, Professor Fitzpatrick's studies showed that Cysteamine is significantly stronger than hydroquinone in vivo, but its intense odor prohibited its use in topical products.

In 2010, Dr Behrooz Kasraee developed a new technology that significantly increases cysteamine stability and reduces its intense odor

In 2013, Dr Christophe Hsu presented at the AAD Annual Meeting the significant efficacy and safety of Cysteamine 5% on a first cohort of 30 melasma patients

Chavin W. et al, 1966. Some Potent Melanin Depigmenting Agents in the Black Goldfish. Die Naturwissenschaften 53(16):413-414
E Frenk et al. 1968. Selective Action of Mercaptoethylamines on Melanocytes in Mammalian Skin. Arch Dermatol 97 (4), 465-477. 4
SS Bleehen et al. 1968. Depigmention of Skin with Mercaptoamines. J Invest Dermatol 50 (2), 103-117. 2
Hsu et al. 2013. Cysteamine Cream as a new skin depigmenting product. JAAD AB189 P6024.

Cysteamine is a physiological molecule

Cysteamine is **the simplest aminothiol** physiologically produced in humans from the essential amino-acid **cysteine**



Concentrated in human milk, cysteamine acts as an intrinsic antioxidant and is known for its protective role

Physiological Levels of Cysteamine		
Mouse*	Meat	79.6 nmol/g
	Kidney	106.7 nmol/g
	Milk	-
Cow**	Meat	350 µg/l
	Kidney	1330 µg/l
	Milk	124 µg/l
Human**	Milk	2345 µg/l

Sources: data on file

Cysteamine acts on more levels of melanogenesis than any other topical agent

Mechanism of Action	Compound
Tyrosinase inhibitor (6,32)	**Cysteamine**, Hydroquinone, Kojic Acid, Arbutin, Azelaic Acid, Ascorbic Acid, Ellagic acid, Glycolic Acid, EGF, 4-n-butylresorcinol
Dopa oxidase inhibitor (6,32)	**Cysteamine**, Mulberry extract
Peroxidase substrates / inhibitors (6,32)	**Cysteamine**, Hydroquinone
Increasing intracellular glutathione (6,32)	**Cysteamine**
Removal of melanin precursors (6,33)	**Cysteamine,** 2-Mercaptonicotinoyl glycine
Melanosomal transfer inhibition (32)	Isobionic-Amide, Niacinamide, Tretinoin, Dioic acid
Block plasmin pathway (32)	Tranexamic acid
Anti-hormonal (32)	Flutamide
Increase keratinocyte turnover (32)	Tretinoin, Glycolic Acid
Cytotoxic (32)	Hydroquinone, Azelaic Acid

(1) Austin, Evan, Julie K. Nguyen, and Jared Jagdeo. Journal of drugs in dermatology: JDD 18.11 (2019).
(2) Data on file

Cysteamine – A naturally-occuring antioxidant with multiple effects on the melanogenesis pathways

Enzymatic Pathway :
- Inhibition of **tyrosine hydroxylation** [1]
- **Inhibition** of DOPA oxidation [1]
- **Inhibition** of indole polymerisation through peroxidase inhibition [1]

Iron Chelation Pathway :
- **Inhibition** of Fenton-type reactions through iron and copper ion quenching [2,3]
- **Quenching** of dopaquinone [5]

Glutathione cascade impeding effect :
- Increase of **intra-cellular glutathione** bypassing Eu-melanin pathway [3,4]

Other effects :
- **Antioxidant effect** Redox “bleaching” of dark melanin in stratum corneum into a lighter form [6,7]
- **Keratolytic effect** – Removal of superficial epidermal layers containing melanin and acceleration of epidermal turnover [7-10]
- **Keratocyte proliferation** – Epidermal texture thickening



[1] Wood J M, et al (1991). Studies on the reactions between human tyrosinase, superoxide anion, hydrogen peroxide and thiols. *Biochim Biophys Acta*, 1074(3), 378-385.
[2] Sakurai H, et al. (1971). Studies on the sulfur-containing chelating agents [...]. *Chem Pharm Bull*, 19(7), 1416-1423.
[3] de Matos D G, et al. (1995). Effect of cysteamine on glutathione level [...]. *Mol Reprod Dev*, 42(4), 432-436.
[4] Parvez S, et al (2006). Survey and mechanism of skin depigmenting and lightening agents. *Phytother Res*, 20(11), 921-934.
[5] Alfieri, M. Let al. (2022). Disentangling the puzzling regiochemistry of thiol addition to o-quinones.. *J. Org. Chem.*, *87*(7), 4580-4589.
[6] Meredith P, Sarna T. The physical and chemical properties of eumelanin. Pigment Cell Res. 2006;19:572–594.
[7] Gillbro JM et al.(2011). The melanogenesis and mechanisms of skin-lightening agents–existing and new approaches. *Int J Cosmet Sci*, 33(3), 210-221.
[8] Manuszak MA, et al.. (1996). single-fiber tensile kinetic data. *J. Soc. Cosmet Chem*, 47, 213-227.
[9] Cruz CF, et al. (2016). Human hair and the impact of cosmetic procedures: a review on cleansing and shape-modulating cosmetics. *Cosmetics*, 3(3), 26.
[10] Stratigos AJ, et al.. (2004). Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. *Am J Clin Dermatol*, 5(3), 161-168.

Clinical Evidences

UpToDate Melasma Management Algorithm

Cyspera® Cysteamine is key in the algorithm to manage stubborn dyschromia.

Wolters Kluwer UpToDate®

It is a first line non-HQ option that can also be used routinely for long-term maintenance. (1)

– Pearl Grimes, MD
– Valery Callender, MD

BJD British Journal of Dermatology

Significant efficacy on melasma
Double-blind, randomized clinical study on 50 epidermal melasma patients(1)

DermatologicaSinica

Significant efficacy on PIH
Double-blind, randomized vehicle-controlled clinical study on 40 patients with PIH induced by acne or by laser(3)

JCD Journal of Cosmetic Dermatology

Significant efficacy on photoaging dyschromia
Case series involving 7 patients with photoaged skin (5)

JDD Journal of Drugs in Dermatology

Equal efficacy, faster onset of action vs Kligman's formula
Double-blind, randomized clinical study on 80 epidermal melasma patients(2)

Springer Archives of Dermatological Research

As effective with less complication than TXA mesotherapy
Comparison of Cyspera vs. Tranexamic acid mesotherapy in a randomized clinical study of 54 melasma patients (4)

JCAD Journal of Clinical and Aesthetic Dermatology

Pairs well with in-office procedure
Case study of the successful combination of the IBA-Cysteamine Complex with picosecond laser for a recalcitrant melasma patient(6)

(1) Mansouri et al, British Journal of Dermatology (2015) 173, pp209–217
(2) Sachdev, Grimes PE, Callender, et al. Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action. J Drugs Dermatol JDD. 2024;23(2):9-16
(3) Liu R, Tsai TF, Lai YJ, Ng 黃昭瑜 CY. Efficacy and safety of cysteamine-isobionicamide complex in postinflammatory hyperpigmentation: A 16-week, randomized, double-blinded, vehicle-controlled trial. Dermatol Sin. 2023;41:222-230
(4) Karrabi et al. Arch Dermatol Res. 2 Sep 2020
(5) Clark-Loeser L, Sfriso, Riccardo, Dirlewanger, Laure, Kasraee B. A case series with cysteamine-isobionicamide Complex: Clues for Skin rejuvenating activity. *J Cosmet Dermatol.* 2025;24(1):e16743.
(6) Hartman C, Crawford M, Frey C, Bosley R, Sfriso R, Dirlewanger L, Kasraee B. Successful Treatment of recalcitrant melasma by Picolaser and Isobionicamide – Cysteamine combination: a Case Report. J *Clin Aesthet Dermatol*. 2025;18(2):30–32

scientis THE PIGMENTATION AUTHORITY

Cyspera Pigment Correction

INTENSIVE
Cysteamine 7%
IBA 3%

Strongest formulation
for safe, fast and effective
pigment correction.

SENSITIVE
Cysteamine 5%
IBA 5%

Powerful pigment correction,
also for sensitive skin.

Cysteamine is a naturally occurring molecule that provides powerful antioxidant activity and targets multiple steps in the melanogenesis pathway for effective pigment correction.

- Clinically proven pigment correction
- Safe and effective, Hydroquinone free
- Exclusive Cysteamine Isobionic-Amide Complex
- For all skin types, including sensitive
- Providing better skin health/quality, even skin tone, and bright complexion
- Non-photosensitive, Suitable for round-year use and long-term use
- Works well with in-office procedures

What is **Isobionic-Amide**?

Isobionic-Amide : a new Anti-Inflammatory agent



- ✓ **Isobionic-Amide** (IBA) is **naturally found** in root exudates of common bean (Phaseolus vulgaris L.), and in Garcinia Kola, a plant **used in traditional African medicine**. (2) Garcinia Kola has been reported to have **anti-inflammatory**, **anti-oxidative** and **antibacterial activity**. (3)

- ✓ **IBA is a Generally Recognized Safe (GRAS)** compound substance. Also known as Isonicotinamide, IBA is a non-metabolized isomer of nicotinamide (Vitamin B3). It is commonly used for material synthesis and pharmaceutical development due to its cocrystallisation properties that improve drug bioavailability. (1)

In 2011, Dr. Behrooz Kasraee was studying the efficacy of isomers of the pyridine family. By analogy to the Biphenol family, he established **the superior efficacy of IsoBionic-Amide** (4)

Pyridine:



Isobionic-Amide

> potency



Picolinamide

> potency



Niacinamide

Chemical isomers configuration: Para ---------- Ortho ---------- Meta

	Hydroquinone	Catechol	Resorcinol
Biphenol :		> potency 	> potency 

(1) Zhang et al.. J Mol Struct. 5 juin 2021;1233:130048.
(2) Assanti, et al. (2022) J Med Active Plants 11, no 1 (mars 2022): 1-21. https://doi.org/10.7275/hece-wp36.
(3) Tawaraya et al (2014), Metabolites 2014, 4, 599-611. https://doi.org/10.3390/metabo4030599
(4) Kasraee et al. (2011) Experimental Dermatology

Anti-inflammatory effects of Isobionic-Amide (Cyspera® “Boost”)

ISOBIONIC-AMIDE

22 female subjects

18 – 45 years old

Phototype: I – III



(Natural recovery process) (applied daily after SLS patch removal)

Cyspera Boost™ accelerates the skin’s natural recovery process and reduces skin erythema:

- ✓ By **40%** in just 30 minutes with one single application
- ✓ By **85%** in 3 days with just 3 applications
- ✓ Transepidermal water loss (indicating skin barrier repair) was also improved by 31%

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

IBA protects the skin from UV-induced erythema

ISOBIONIC-AMIDE

5 hours post-UVB irradiation

the erythema index was measured using SkinColorCatch®

UVB | Boost™ pretreated | Baseline



*, p<0.05

Depigmenting activity of Isobionic-Amide

ISOBIONIC-AMIDE

Depigmenting activity of Isobionic-Amide[1]

- Discovered through analysis of pyridine isomer configuration
- Established in 2011 to act as Pigment control by:
  - Inhibition of melanosomal transfer



  - Inhibition of tyrosinase



Multiplying 6x the tyrosinase inhibition activity [2]

- Isobionic-Amide multiplies by 6x the tyrosinase inhibition effects when applied in combination with Cysteamine



(1) Kasraee et al. (2011) Experimental Dermatology
(2) Kasraee B. (2024). J Am Acad Dermatol.; 91 (3) : AB245

scientis
THE PIGMENTATION AUTHORITY

Isobionic-Amide acts as an InflammAging modulator on melanocytes

ISOBIONIC-AMIDE

Protect melanocytes against low-chronic inflammation through PARP-1 & COX-2 inhibition

- **Anti-inflammation :**

  PARP-1, COX-2 and NF-κB inhibition contributes to soothing chronic, low-grade inflammation. [1, 2, 3]

- **Photoprotection:**

  SIRT 1-6 activation and COX-2, MMP-1, TNFa & IL8 inhibitions protect from UV-induced inflammasome and erythema, edema, hyperplastic and hyperpigmentation. [4, 5, 6]

- **Photoaging:**

  PGE-2 & MITF inhibition has anti-melanogenesis effects through melanin synthesis and melanosomal transfert inhibition in synergy with Cysteamine [6,7,8]



Promotes cellular repair and resilience by enhancing NAD⁺ availability and SIRT-1 activation

- **Cellular Repair:**

  Increased intracellular NAD⁺ supports cellular energy and repair, and AGEs inhibition promotes higher cellular viability and inhibition of cellular senescence [5,6]

- **Anti-Oxidative effects:**

  NAD+ & SIRT-1 reduces oxidative stress and limits free radical damage both linked to UV exposure and pigmentation irregularity [4,5]

- **Barrier & matrix repair:**

  Sirt1 activation & PGE-2 inhibition promote Collagen & extracellular matrix production in dermis and keratinocyte proliferation in epidermis, restore skin barrier and resilience in photoaged or stressed [9, 10]

(1) Chiu et al., *FASEB Journal*, 2021
(2) Conlon NJ. (2022) The Role of NAD+ in Regenerative Medicine. Plast Reconstr Surg. 150(4 Suppl):41S-48S
(3) Data on File, *Scientis SA Boost Study*, 2021 (SLS-induced erythema model)
(4) Lautrup et al. (2024) Roles of NAD+ in Health and Aging. Cold Spring Harb Perspect Med. Cold Spring Harbor Laboratory Press; 14(1):a041193
(5) Odoh et al (2022) The role of NAD and NAD precursors on longevity and lifespan modulation in the budding yeast, Saccharomyces cerevisiae. Biogerontology. 23(2):169-99
(6) Fuller (2019) Role of PGE-2 and Other Inflammatory Mediators in Skin Aging and Their Inhibition by Topical Natural Anti-Inflammatories. Cosmetics. Multidisciplinary Digital Publishing Institute; 6(1):6
(7) Kasraee et al. (2011) Experimental Dermatology
(8) Kasraee B. (2024). J Am Acad Dermatol.; 91 (3) : AB245
(9) Shim JH. (2019) Prostaglandin E2 Induces Skin Aging via E-Prostanoid 1 in Normal Human Dermal Fibroblasts. Int J Mol Sci. 20(22):5555.
(10) Data on File, *Scientis SA Texture Study*, 2024 (PRIMOS-CR®)

⊕ : Activation ⊘ : Inhibition

Textural activity and auxiliary benefits of Isobionic-Amide

ISOBIONIC-AMIDE

Reversed signs of photoaging measured in 95% of subjects



8 weeks
Twice-daily application
22 female subjects
55 – 70 years old
Phototype: I – IV



D0

D56

Data on File (Scientis SA)

Part 3



Intensive Duo Pigment Correction

CYSPERA INTENSIVE | Cys. 7% + IBA 3%
CYSPERA BOOST | IBA 5%

INTENSIVE DUO Pigment Correction



INTENSIVE
Cysteamine 7%
IBA 3%



Most power formulation for safe, fast and effective pigment correction.

INFLAMMAGING
Isobionic Amide 5%

Restore skin inflammaging, revealing a vibrant and resilient complexion

CYSPERA INTENSIVE DUO combines our most powerful Cysteamine formulation with Isobionic-Amide (IBA) to deliver the highest level of pigment correction in the Cyspera range. Clinically proven, this synergistic duo promotes a more even tone, visibly radiant skin, and improved overall skin health, while maintaining optimal tolerability, even with daily use.

- Synergistic protocol combining pigment correction and Isobionic amide (IBA)
- Faster and more visible results vs. monotherapy
- Promotes a more even, radiant, and healthy-looking complexion
- Enhances tolerability, ideal for daily use on face and body

Gold Standard Efficacy with Cysteamine Isobionic-Amide Depigmenting Complex



A double blind, randomized and placebo-controlled study to investigate the **safety and efficacy** of Cysteamine Isobionic-Amide Depigmenting Complex compared to modified Kligman's formula for the treatment of melasma.

- ✓ **Cyspera® Intensive System**= Isobionic-Amide Cysteamine depigmenting complex (N=30)
- ✓ **Tri-luma® Kligman's Formula**= 4% Hydroquinone, 0.05% tretinoin and 0.01% Fluocinolone Acetonide (N=30)
- ✓ Placebo (N=20)

FEBRUARY 2024 9 VOLUME 23 • ISSUE 2
COPYRIGHT © 2024 ORIGINAL ARTICLE JOURNAL OF DRUGS IN DERMATOLOGY

Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action

Mukta Sachdev MD,[a] Pearl E. Grimes MD,[b] Valerie Callender MD,[c] Corey L. Hartman MD,[d] Susan C. Taylor MD,[e] Nada Elbuluk MD MSc,[f] Ashraf Badawi MD,[g] Yoko Funasaka MD PhD,[h] Joyce Lim MD,[i] Chau Yee Ng MD,[j] Seemal R. Desai MD[k]

[a]Department of Dermatology, Manipal Hospital, Bangalore, India
[b]Dermatology University of California, Los Angeles, CA
[c]Howard University College of Medicine Medical Director, Callender Dermatology & Cosmetic Center, Founder & Principal Investigator, Callender Center for Clinical Research, Glen Dale, MD
[d]Skin Wellness Dermatology, Birmingham, AL
[e]Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
[f]USC Department of Dermatology, Keck School of Medicine, CA
[g]Laser Institute, Cairo University, Egypt
[h]Department of Dermatology, Nippon Medical School, Tokyo, Japan
[i]Joyce Lim Skin and Laser Clinic, Singapore
[j]Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Linkou, Taiwan Vitiligo Clinic, and Pigment Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan Department of Dermatology and Aesthetic Medicine Center, Jen-Ai Hospital, Taichung, Taiwan
[k]Department of Dermatology, The University of Texas Southwestern Medical Center, and Innovative Dermatology, Dallas, TX

Inclusion Criteria n=70

- Female subjects aged 25-45 years
- Subjects of skin phototype III-IV
- Subjects with moderate-to-severe melasma
- Subjects with Mixed or Epidermal Melasma

Exclusion Criteria

- Subjects with only dermal Melasma
- Subjects with on hormonal therapy
- Subjects who had a skin lightening procedure or who've been treated with Hydroquinone in the past 8 weeks

Sachdev M, et al. 2024. J Drugs Dermatology; 23:2 pp9-15

Cyspera® as effective & fast onset of action as Triluma®





✓ Improved melasma appearance as effectively as Triluma®

✓ Melasma severity is significantly reduced as early as week 4

Sachdev M, et al. 2024. J Drugs Dermatology; 23:2 pp9-15

*** : versus baseline, p<0.001; n-s: non significative between groups

scientis
THE PIGMENTATION AUTHORITY

Higher Patient Satisfaction with Cyspera® vs. Triluma®



Patients' Satisfaction



Improvement of Quality of life



Placebo (N=20)

Kligman's Formula
= 4% Hydroquinone, 0.05% tretinoin and 0.01% Fluocinolone Acetonide (N=30)

Cyspera® Intensive System
= Isobionic-Amide Cysteamine Pigment Correction Complex (N=30)

Sachdev M, et al. 2024. J Drugs Dermatology
*** : versus baseline, p<0.001; n-s: non significative between groups

scientis
THE PIGMENTATION AUTHORITY

Better efficacy / tolerability profile of **Cyspera® vs. TXA mesotherapy**



Comparison of Evolution in mMASI Score





✓ Equal efficacy in mMASI score reduction

✓ Much less complications Cyspera® vs. TXA mesotherapy

Karrabi et al, 2020, Arch Dermatol Res.;
Protocol: Study on 54 epidermal melasma patients; CYS: 30 min daily application; visit 2 at 8 weeks & visit 3 at 16 weeks. TXA meso in-office application every 4 weeks; Note: P value : P0 = 0.090, P1 = 0.365 & P2 = 0.952; P<0.001 for all comparisons
*** : versus baseline, p<0.001; n-s: non significative between groups

scientis
THE PIGMENTATION AUTHORITY

Cyspera® **INTENSIVE**, effects on melasma



Before

After 8 weeks
(15min daily application)

© courtesy Behrooz Kasraee, MD, 2021

Cysteamine IBA Depigmenting Complex, **effects on melasma**



Baseline

Week 8

Source: Christine Adams, NP-BC, Owner of Skinsplendid, LLC

skinsplendid™

scientis THE PIGMENTATION AUTHORITY

Cysteamine IBA Depigmenting Complex, effects on PIH





Baseline

Week 16

Courtesy of Dr Chau Yee Ng (Taiwan)

Liu RT, Tsai T, Lai Y, Ng, CY. Efficacy and safety of cysteamine-isobionicamide complex in postinflammatory hyperpigmentation: A 16-week, randomized, double-blinded, vehicle-controlled trial. *Dermatologica Sinica*.2023;41(4)222-230.

Cysteamine IBA safety and efficacy in combination with retinoids

(original formulation in combination therapy with tarazotene .1% cream (Tazorac®)

Baseline

Week 12

Dr. Corey Hartman skin wellness DERMATOLOGY

Part 4



Sensitive Duo Pigment Correction

CYSPERA ORIGINAL+ | Cys. 5% + IBA 5%
CYSPERA BOOST | IBA 5%

SENSITIVE DUO – Powerful pigment correction for sensitive skin.



ORIGINAL+

Powerful pigment correction, also for sensitive skin.

Cysteamine 5%
Isobionic-Amide 5%

BOOST

Restore skin inflammaging, revealing a vibrant and resilient complexion

Isobionic Amide 5%

CYSPERA SENSITIVE is the cysteamine-based formulation designed to actively manage pigmentation concerns in sensitive and compromised skins, including intimate areas. Powerful yet gentle, it restores skin tone uniformity, comfort, and a naturally healthy glow.

SENSITIVE DUO combines the pigment-correcting power of Cysteamine with the skin-soothing benefits of Isobionic-Amide (IBA) to offer a complete solution for sensitive and compromised skin, including intimate areas.

Mode of Use:

- **Sensitive skin** (low-chronic inflammation, aging, dry, thin & exposed skin types): full-face short-contact application for 3-5 min daily, rinse-off then leave-on Ageless
- **Compromised skin** (irritation-, atopic-, eczema-, erythema-prone skin): moisturize first then full-face short-contact application for 2 min every 2 days, rinse-off and leave-on Ageless
- **Intimate area** (semi-mucosa; neeples; under-arms; bikini-lines): full-area short-contact application for 5 min daily.

Benefits: Pigment Correction | Safe on sensitive / compromised skin | Intimate / external genital area | Photoaging correction | Enhanced skin comfort | Antioxidant | Skin radiance & brightening | Skin tone evenness

Effects on Photoageing Dyschromia



Baseline



Week 6

Courtesy from Dr. Utako Kimura

Safety and Efficacy on periorbital hyperpigmentation

CYSTEAMINE + ISOBIONIC-AMIDE



Baseline



Week 12

skin wellness DERMATOLOGY

Dr. Corey Hartman Patient prior usage of cojic/ arbutin/ HQ 8% BID 4 weeks, Switched to Cyspera 5% (original), QD 20 weeks

scientis THE PIGMENTATION AUTHORITY

Safety and Efficacy on thin skinned areas, original formulation

Baseline

Day 19

Data on file, @ CDC Geneva 2018, Cyspera 5% (original)

Effects on solar lentigo



Baseline

Week 12

Dr. Saki, HSR 2024, *Successful treatment of solar lentigines by topical application of stabilized cysteamine: A vehicle-controlled, double-blind randomized study. Cyspera 5%* (original)

Cysteamine safety and efficacy for pigmented scars



Baseline

Week 4

Source: Dr.Mai Ahmad

Cyspera 5% (original)

scientis
THE PIGMENTATION AUTHORITY



Effects on ACNE – Active & PIH

CYSTEAMINE – ISOBIONIC-AMIDE COMPLEX

Effects on Active Acne of IBA Cysteamine Complex

CYSTEAMINE + ISOBIONIC-AMIDE

Baseline



3 days



2 Weeks



Post-Acne PIH

Protocol: 1) Intensive (15min); 2) Neutralize (rinse-off); 3) Boost (day & night)

Data on file

scientis THE PIGMENTATION AUTHORITY

Effects on acne, PIH, hypopigmentation from picking

- Patient with acne, PIH, hypopigmentation from picking
- Treated acne with sarecycline, benzoyl peroxide cleanser and adapalene
- Added Cyspera 15-minutes daily before acne completely resolved
- Stopped oral antibiotics after 12-weeks and continued other topicals with Cyspera
- No irritation

Baseline

16-weeks

© courtesy of Corey Hartman, MD, 2021

Significant efficacy in Managing PIH with Cyspera®



A double blind, randomized and placebo-controlled study to investigate the **safety and efficacy** of Cysteamine Isobionic-Amide Depigmenting Complex in managing PIH.

- ✓ **Cyspera® Intensive** System= Isobionic-Amide Cysteamine depigmenting complex (N=20)
- ✓ **Placebo** (N=20)

Dermatologica Sinica

journal homepage: http://journals.lww.com/DERS

Original Article

Efficacy and safety of cysteamine-isobionicamide complex in postinflammatory hyperpigmentation: A 16-week, randomized, double-blinded, vehicle-controlled trial

Rosalie Tzu-Li Liu[1,2], Tsung-Fu Tsai[1,2,3], Yi-Jing Lai[1,2,3,4], Chau Yee Ng[1,2,3,4*]

[1]Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan, [2]School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan, [3]Vitiligo Clinic and Pigment Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan, [4]Department of Dermatology and Aesthetic Medicine Center, Jen Ai Hospital, Tai-Chung, Taiwan

Inclusion Criteria
N=40

- 20 years old in age and
- experienced more than 12 weeks of acquired hyperpigmentation following acne or laser therapy

Exclusion Criteria

- patients with ongoing inflammatory symptoms, and/or under anti-inflammatory medications,
- pregnant patients
- patients undergoing hormone therapy and/or oral contraceptives,
- patients presenting with dermal hyperpigmentation without epidermal involvement, and
- patients with a known history of allergic reactions to the product.

Rosalie Tzu-Li Liu et al. 2023. Dermatologica Sinica, 41 (4), 222-230

Significant improvements of Mexameter Melanin Index, Investigator assessments and Patient scores with Cyspera **on Managing PIH**

CYSTEAMINE + ISOBIONIC-AMIDE



eter® and skin imaging analysis (VISIA skin analyzer) for the efficacy of cysteamine-isobionicamide complex in hyperpigmentation (a) Mexameter melanin index; (b) Mexameter erythema index; (c) VISIA skin analysis – surface s skin analysis – brown spots absolute scores.



Figure 2: (a) Investigator global assessment. A significant improvement in postinflammatory hyperpigmentation was found for week 4 of treatment 4, $P < 0.05$, week 8, $P < 0.001$). (b) Patient Global Assessment. A significant improvement in postinflammatory hyperpigmentation was fou week 12 of treatment (week 12, $P < 0.05$, week 8, $P < 0.001$).

Rosalie Tzu-Li Liu et al. 2023. Dermatalogica Sinica, 41 (4), 222-230

scientis THE PIGMENTATION AUTHORITY

Significant efficacy in Managing Acne-induced PIH with Cyspera®



A investigator blind, randomized and controlled study to investigate the safety and efficacy of Cysteamine vs. HQ in Treating Acne-induced Post-inflammatory hyperpigmentation

- ✓ **Cyspera®** Cysteamine 5% (N=13)
- ✓ **Hydroquinone 4%/ ascorbic acid 3%** (N=15)

Assessing the Effectiveness of Stabilized Cysteamine 5% Cream Compared to Hydroquinone 4%/Ascorbic Acid 3% Combination Cream in Treating Acne-induced Post-inflammatory Hyperpigmentation: A Randomized, Controlled Study

by KOOROSH AHMADI, MD; AMIR MIRI, MD; ZEINAB BIZAVAL, MD; MOZHDEH SEPASKHAH, MD; SARA RANJBAR, MSc; ZAHRA BAGHERI, PhD; and BEHROOZ KASRAEE, MD

Drs. Ahmadi, Miri, and Bizaval are with the Department of Dermatology and School of Medicine at Shiraz University of Medical Sciences in Shiraz, Iran. Dr. Sepaskhah is with the Department of Dermatology, School of Medicine, and Molecular Dermatology Research Center at Shiraz University of Medical Sciences in Shiraz, Iran. Ms. Ranjbar is with the Molecular Dermatology Research Center at Shiraz University of Medical Sciences in Shiraz, Iran. Dr. Bagheri is with the Department of Biostatistics and School of Medicine at Shiraz University of Medical Sciences in Shiraz, Iran. Dr. Kasraee is with Scientis SA in Geneva, Switzerland.

J Clin Aesthet Dermatol. 2024;17(4):37–41.

OBJECTIVE: Postinflammatory hyperpigmentation (PIH) is a common sequela of acne vulgaris. Topical treatment with hydroquinone is the standard treatment, but may be associated with complications. Cysteamine is a relatively safe depigmenting agent with an observed depigmenting effect. We designed this study to assess the efficacy of a cysteamine 5% cream in treating acne-induced PIH. **METHODS:** Twenty-eight out of 32 participants finalized this investigator-blind, randomized, and controlled trial (registered in Iranian Registry of Clinical Trials [IRCTID: IRCT20140212016557N5]). We randomized the patients to apply either cysteamine 5% or hydroquinone 4%/ascorbic acid 3% (HC) cream. Postacne hyperpigmentation index (PAHPI) and melanin index were the assessment measures after four months of treatment. We evaluated the quality of life by the Dermatology Life Quality Index (DLQI) questionnaire. **RESULTS:** Both cysteamine and HC cream significantly decreased the PAHPI score and melanin index of acne-induced PIH patients ($p<0.05$). The decrease in PAHPI score and melanin index were not significantly different in treatment groups after four months ($p>0.05$). Quality of life ameliorated significantly only with cysteamine treatment. However, no significant change in quality of life was observed between groups. **LIMITATIONS:** Limitations of our study include the relatively small sample size and absence of follow-up. **CONCLUSION:** Cysteamine cream is an effective treatment of post-acne PIH, with similar efficacy to the accepted treatment of PIH, i.e., hydroquinone cream. **KEYWORDS:** Acne vulgaris, hyperpigmentation, drug therapy, cysteamine, hydroquinone, ascorbic acid, administration, topical

Inclusion Criteria
N=28 of 32

- *patients between 14 and 40 years of age who had*
- *no active inflammatory acne lesions after receiving any kind of antiacne treatment*

Exclusion Criteria

- *patients receiving any depigmenting agent two months before being recruited in the study,*
- *patients with a history of hypersensitivity to ingredients of either drug*
- *pregnant or lactating patients.*

Koorosh Ahmadi et al. 2024. *J Clin Aesthet Dermatol. 2024;17(4):37–41*

scientis THE PIGMENTATION AUTHORITY

Gold Standard Efficacy with Cyspera®



TABLE 2. Effect of treatment on different variables and comparison of the therapeutic effects in cysteamine cream and Hydroquinone 4%/ascorbic acid 3% cream-treated acne-induced post-inflammatory hyperpigmentation patients, based on both intention-to treat and per-protocol approaches

VARIABLES	CYSTEAMINE				HYDROQUINONE 4%/ASCORBIC ACID 3%				*P*-VALUE[b]
	BEFORE	AFTER	*P*-VALUE[w]	DELTA*	BEFORE	AFTER	*P*-VALUE[w]	DELTA*	
ITT RESULTS	MEAN±SD	MEAN±SD		MEAN±SD	MEAN±SD	MEAN±SD		MEAN±SD	
PAHPI score	11.39 ± 3.01	8.97 ± 3.32	0.049	2.41 ± 4.51	9.50 ± 2.64	6.59 ± 2.64	0.004	2.90 ± 3.76	0.732
Melanin index	123.04 ± 58.69	77.09 ± 22.55	0.005	45.94 ± 56.05	103 ± 66.70	57.19 ± 30.33	0.015	46.80 ± 73.29	0.970
DLQI	7.56 ± 6.63	3.94 ± 3.97	0.013	3.61 ± 5.16	3.94 ± 4.88	1.95 ± 2.35	0.058	1.98 ± 4.15	0.316
Per-protocol results									
PAHPI score	11.54 ± 2.87	8.92 ± 2.56	0.014	2.62 ± 3.28	9.33 ± 2.84	7.13 ± 2.06	0.033	2.20 ± 3.61	0.754
Melanin index	117.78 ± 55.62	72.36 ± 21.18	0.012	45.41 ± 55.74	106.71 ± 71.52	55.37 ± 27.79	0.019	51.34 ± 75.10	0.817
DLQI	8.07 ± 6.86	3.71 ± 3.73	0.007	4.36 ± 5.04	4.00 ± 5.19	1.94 ± 2.48	0.082	2.06 ± 4.41	0.195

ITT: Intention-to-treat; PAHPI: postacne hyperpigmentation index; DLQI: Dermatology Life Quality Index; SD: Standard deviation
*Difference of variables before and after treatment
p-value[w]: *p*-value based on paired samples *t*-test for comparing variables before and after study,
p-value[b]: *p*-value based on independent two-sample *t*-test for comparing Delta score between two groups.

- *Both cysteamine and HC cream significantly reduced the PAHPI score and melanin index of acne-induced PIH patients in ITT and PP approaches (Table 2).*
- *no significant decrease was observed in delta scores of PAHPI and melanin index between the two treatment groups after four months of treatment (Table 2).*
- *Quality of life improved significantly after treatment with cysteamine, but the improvement was not significant after HC cream therapy (Table 2).*
- *the difference in improvement of DLQI between the treatment groups was not statistically significant (Table 2).*
- *Post-treatment patient global assessment (Month 4) was 3.46±0.87 in the cysteamine group and 4.07±1.03 in the HC cream group and was not different between groups (p=0.068).*

Koorosh Ahmadi et al. 2024. *J Clin Aesthet Dermatol. 2024;17(4):37–41*



InflammAging Signs Defense

CYSPERA BOOST | IBA 5%

InflammAging-prone Skin Defense



ISOBIONIC-AMIDE

CYSPERA BOOST with Isobionic-Amide (IBA), restores skin affected by inflammaging, revealing a vibrant, resilient and healthy skin complexion. Used to enhance the results of CYSPERA Pigment Correction products, or alone as part of your skin care routine

- Helps reduce signs of inflammation, irritation and erythema
- Enhances the visible results of pigment correction
- Improves skin radiance, health and overall quality, and supports skin barrier function and resilience

Cyspera Boost – Multi-modal effects for Inflamm-Aging & Photo-Aging

Vitamin C
0.9% ascorbyl palmitate (lipophilic) + 0.9% sodium ascorbyl phosphate (hydrophilic)

Lightens melanin & brightens
Skin Glow

IBA
5% Isobionic-Amide

Defends melanocytes from low chronic inflammation
InflammAging



Panthenol (2.5%)
& NMF (6.4% glycerin, 1% Xylitylglucoside)

Strengthens the skin barrier
Soothing

Retinol (0.075%)

Accelerates skin's renewal process
Anti-Aging Texture



ISOBIONIC-AMIDE

scientis
THE PIGMENTATION AUTHORITY

Anti-inflammatory effects of Isobionic-Amide (monotherapy)

ISOBIONIC-AMIDE

Baseline

Week 16

Dr. Kentaro Oku, Yokohama Japan, 2024

scientis
THE PIGMENTATION AUTHORITY

Reversed signs of Photoaging of Isobionic-Amide



Baseline



Week 8, twice daily application of CYSPERA BOOST

ISOBIONIC-AMIDE

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

Reversed signs of Photoaging of Isobionic-Amide

ISOBIONIC-AMIDE

Baseline

Lighter, more even, more luminous complexion

Week 8

Less under-eye pigmentation

Data on File (Scientis SA)

Reversed signs of Photoaging of Isobionic-Amide

ISOBIONIC-AMIDE



Baseline

Week 8, twice daily application

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

Reversed signs of Photoaging of Isobionic-Amide



ISOBIONIC-AMIDE

Baseline



Week 8, twice daily application

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

Reversed signs of Photoaging of Isobionic-Amide



ISOBIONIC-AMIDE



Baseline

Week 8, twice daily application

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

InflammAging Signs Defense

ISOBIONIC-AMIDE

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

Photo-Aging effects visible as early as 4 weeks

Cyspera Boost™



In-Use Test, 31 volunteers, 4 weeks of daily product application

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

Photo-Aging effects visible as early as 4 weeks

Cyspera Boost™

Measured quantitatively by Dermacatch

64% of patients with **lighter skin spots**

60% of patients with **lighter overall skin tone**

- Up to 30% lighter melanin index

Patient's Self-Assessment

91% of patients with improved **overall skin appearance**

82% of patients with **lighter skin complexion**

82% of patients with more **even** skin complexion

86% of patients with more **radiant** and more **luminous** skin

In-Use Test, 22 volunteers, 8 weeks of twice daily product application

Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

InflammAging effects of Isobionic-Amide

Independent study done by J.S. HAMILTON POLAND

Population

22 female subjects

18 – 45 years old

Phototype: I - III

Devices

Mexameter®: measurement of skin irritation

Tewameter®: measurement of Transepidermal water loss.

Study design

SLS: Sodium Lauryl Sulfate*

SLS is applied on skin and a patch is positioned on top of it



After 24h the skin develops irritation



HAMILTON J.S. POLAND, Data on File (Scientis SA)

InflammAging effects of Isobionic-Amide

22 female subjects

18 – 45 years old

Phototype: I – III



Cyspera Boost™ accelerates the skin's natural recovery process and reduces skin erythema:

- ✓ By **40%** in just 30 minutes with one single application
- ✓ By **85%** in 3 days with just 3 applications
- ✓ Transepidermal water loss (indicating skin barrier repair) was also improved by 31%

HAMILTON J.S. POLAND, Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

Protective effects of Isobionic-Amide from UV-induced inflammation (1/5)

Treatments:

- Untreated
- UVB alone
- Cyspera Boost™ applied 5 minutes before UVB exposure

Endpoints:

- Measurement of melanin, erythema and skin color
- Photographs



Data on File (Scientis SA)
To see how SkinColorCatch works: https://vimeo.com/579347278

Protective effects of Isobionic-Amide from UV-induced inflammation (2/5)

5 hours post-UVB irradiation, the erythema index was measured using SkinColorCatch®

UVB

Boost™ pretreated +UVB



Data on File (Scientis SA)

scientis THE PIGMENTATION AUTHORITY

Protective effects of Isobionic-Amide from UV-induced inflammation (3/5)

7 days post UV irradiation, the erythema index was measured using SkinColorCatch®

UVB

Boost™ pretreated + UVB



Data on File (Scientis SA)

Protective effects of Isobionic-Amide from UV-induced inflammation (4/5)

The skin was pre-treated with Cyspera Boost™ 5 minutes before UVB irradiation

14 days later, the erythema index was measured using SkinColorCatch®

UVB

Boost™ pretreated +UVB



Data on File (Scientis SA)

scientis
THE PIGMENTATION AUTHORITY

Non-Phototoxicity of Cyspera® Boost Isobionic-Amide

Independent study done by EUROSAFE France

In vitro



Reconstructed Human Epidermis (SkinEthic)

OCDE guidelines N° 432

Positive control : Phenergan 2%

End Points

Cellular viability: quantified by MTT-formazan

Study design

	Product Application	UVA Irradiation
Untreated	∅	6 J/cm²
Boost™	Boost™	6 J/cm²
Positive control	Phenergan 2%	6 J/cm²



EUROSAFE France, Data on File (Scientis SA)

Cyspera Boost™ is not phototoxic

OCDE Guidelines N°432

	Viability without UVA irradiation	Viability with UVA irradiation	Viability decrease
Untreated	100%	91%	9%
Cyspera Boost™	100%	97%	3%
Positive control : Phenergan 2%	74%	7%	67%



EUROSAFE France, Data on File (Scientis SA)

Cyspera BOOST Isobionic-Amide : a next Generation InflammAging

Patients' self-assessment

82% *reports **lighter and more even skin complexion after 4weeks**[4]*

71% *reports **dark spots fading after only 4 weeks**[1]*

82% *reports improved appearance of pigmented **spots**[4]*

86% *reports **more radiant and luminous skin**[4]*

Prevents UV-induced erythema & darkening[2]

Quantitative measures

64% ***lighter skin spots***

60% ***lighter overall skin tone***

Up to 30% lighter melanin index

PHOTO-AGING

SKIN HEALTH

INFLAMM-AGING

91% *reports **improved overall skin appearance**[4]*

3x *Accelerate the skin natural recovery process[3] after erythema by 3*

2x *Improve skin hydration[3] of dried skin by 2*

Non comedogenic[1], Non phototoxic[4]

-22% *of wrinkle reduction (stat. significant)*[4]

95% *of participants with wrinkle reduction*[4]

84% *of participants show **smoother skin**[1]*

81% *of showed **less dilated and tightened pores**[1]*

[1] under dermatological supervision, 31 volunteers, independent CRO (France, 2021)
[2] Data on File. Reduction of erythema and pigmentation induced by UVB exposure when pre-teated with 1 application of Cyspera Boost™ (2023)
[3] Independent study, volunteers, independent CRO (Poland, 2022)
[3] according to OCDE guidelines, independent CRO (France, 2021)
[4] under dermatological supervision, 22 volunteers, independent CRO (Spain, 2023)

scientis THE PIGMENTATION AUTHORITY



Laser Protocol

CYSTEAMINE – ISOBIONIC-AMIDE

Cyspera Dual Activity for Pre & Post-Procedural Pigment Control & Inflammation Repair

Cysteamine:

The First Physiologic Pigment Corrector

Origin: Endogenous aminothiol, naturally formed during Coenzyme A degradation -- physiologically compatible.

Core actions:

- Inhibition of Tyrosinase & peroxidase activity: reduces DOPA to DOPAquinone conversion
- Fe^{2+} / Cu^{2+} chelation: prevents oxidative catalysis
- DOPAquinone quenching: stops dark indole polymerization
- Increase intracellular glutathione: shifts balance toward lighter melanin
- Protects melanocytes during oxidative stress (laser, RF, UV)

Outcome: Homeostatic modulation of pigmentation. Lightening without cytotoxicity or rebound.

Isobionic-Amide (IBA):

The Next-Generation InflammAging Repair Active

Origin: Redox-stable pyridinecarboxamide, non-metabolized; inspired by natural root exudates (e.g., Garcinia kola).

Core actions:

- Inhibition PARP-1 / COX-2 signaling: dampens chronic inflammation
- Activation of NAD^+ & SIRT-1: boosts cellular repair and detox pathways
- Inhibitin of oxidative stress / AGEs: prevents matrix stiffening
- Increase of collagen synthesis / keratinocyte renewal: restores barrier integrity

Outcome: Cellular protective effect. Protects and rebalances melanocytes, accelerates post-laser recovery, enhances tone uniformity.

Cyspera® provides the new procedural pigment-correction paradigm

Study	Design / Laser Type	Population	Key Findings
Hartman C et al., JCAD 2025	Case (Fitz V) with Picosure 755 nm + Cyspera	Recalcitrant melasma	Marked improvement; no PIH or irritation. PMCID 11896620
Tsai Y-W et al., J Cosmet Dermatol 2025	Split-face RCT with Microneedling RF + Cyspera	Fitz III–IV (n = 30)	Superior mMASI & VISIA improvement vs RF alone; excellent tolerability. DOI 10.1111/jocd.16661
Liu R et al., Dermatol Sinica 2023	16-wk RCT with Cyspera-IBA in post-acne/laser PIH	East Asian (n = 40)	Reduced melanin index and TPHI; improved QoL scores. Link

Key clinical insights :

- Dual protection: Cysteamine + IBA address melanogenic and inflammatory pathways amplified by laser/RF procedures.
- No PIH, no rebound: Across studies, no post-laser PIH or irritation reported when used per short-contact protocol.
- Procedural integration: Ideal for pre-conditioning, post-procedure care, and maintenance in skin of color.

Protocol options

Cyspera® can be used as a stand alone routine, or can be combined with :

Mode of Use:

- ✓ Cyspera® can be applied until skin procedure.
- ✓ After skin procedure, wait for end of redness, desquamation before applying again Cyspera®.

Type of Procedures:

- ✓ Cyspera® can be associated with pigmentary, vascular or ablative lasers, microneedling, Hydrofacial, Derma-abrasion, peelings, etc.

Part 8

Cyspera®

Routines & Mode of Use

INTENSIVE Pigment Correction

for moderate to severe pigmentation concerns



INTENSIVE

Cysteamine 7%
Isobionic-Amide 3.5%

30ml, USD 150

5-15 min. Rince-Off mask application

or

ORIGINAL+

Cysteamine 5%
Isobionic-Amide 5%

30ml, USD 140

3-5 min. Rince-Off mask application

SENSITIVE Pigment Correction

for sensitive skin and intimate area

X

INTENSIVE DUO, USD 205

SENSITIVE DUO, USD 195



epidermal regeneration for
INFLAMAGING
and **Photo-aging**
Dyschromia

BOOST

Isobionic-Amide 5%

30ml, USD 110.-

Leave-on cream application

scientis
THE PIGMENTATION AUTHORITY

Mode of use: 15-minute daily application

can be used on: face body intimate area elbows & knees

Always apply Cyspera® Original+ on a rested skin. Do not wash the skin before application. If necessary to wash, wait for one hour before application.

Step 1

Apply a thin layer on a rested skin and leave on for 15 minutes.

Step 2

Rinse off with neutralize or a gentle cleanser. Gently pat the area dry.

Step 3

Apply boost or a moisturizer. Maintain skin hydration during the day.

#TIPS

- For optimal results, daily use of a broad-spectrum sunscreen with SPF 30 or higher is highly recommended.
- For sensitive skin, it is important for the skin to acclimate to Cyspera® Original+ by limiting initial use to 5 minutes once per day. After one week, increase to 15 minutes exposure (or as advised by your doctor).
- For intimate skin, apply 1 pump of product before showering, leave the cream on for 5 minutes, then rinse off.

INTENSIVE – Intensive Pigment Correction

Cyspera Intensive

Cysteamine IBA Complex
(Cysteamine 7%, Iso-Bionic Amide 3%, Glycolic Acid 3.5%)

Our most powerful formula for safe, fast and effective pigment correction.

Claims and

- ✓ **Clinically proven to reduce melasma and post-inflammatory hyperpigmentation (PIH)**
- ✓ **Promotes a more even skin tone and enhances skin radiance**
- ✓ **Supports visibly renewed skin and improved skin quality**
- ✓ **Safe for daily use, all year round**

Results:

- ✓ **67% pigment correction** after 16 weeks measured by Mexameter[1]
- ✓ **92%** of patients reported **significant improvement in skin appearance[1]**
- ✓ **77%** observed a **healthier-looking complexion[2]**
- ✓ **74%** noticed a **more radiant complexion[2]**

How to Use:

- ✓ **Application**: Apply a thin layer once daily to **unwashed skin for 5-15 minutes**. Start with 5 minutes and gradually increase to 15 minutes.
- ✓ **Routine**: Use during the intensive phase (16 weeks or unless the lesions have disappeared) daily, then reduce to twice a week for maintenance.
- ✓ **Important Note**: Use broad-spectrum sunscreen (SPF 30 or higher) daily for optimal protection. Avoid the use of retinol, AHA, or prescription creams while using Cyspera Intensive.

Data on File. Independent in use study under Dermatological control, Cyspera Intensive and Cyspera Neutralize, 31 volunteers, 4 weeks (France, 2021)

SENSITIVE – Original+ Pigment Correction

Cyspera Original+

Cysteamine IBA Complex
(Cysteamine 5%, Isobionic-Amide 5%)

Powerful pigment correction,
also for sensitive skin.

Claims:

- ✓ **Gentle yet effective solution for daily pigment correction**
- ✓ **Designed for sensitive skin, including intimate areas**
- ✓ **Visibly improves skin tone uniformity and brightness**
- ✓ **Enhances overall skin comfort and smoothness**

Results:

- ✓ **78%** noticed a visible **reduction in pigmentation intensity**[1]
- ✓ **91%** reported **smoother skin**[1]
- ✓ **100%** achieved a **more even tone in intimate areas**[1]
- ✓ **82%** reported **improved appearance in intimate areas**[1]

How to Use:

- ✓ **Application**: Apply to **unwashed skin** once daily, starting with a 3-minute application time, gradually increasing to 5 minutes as skin tolerates. **Rinse off** with a gentle cleanser and **maintain skin moisturized**.
- ✓ **For Intimate Areas**: Use one pump, apply for 5 minutes, then rinse off.
- ✓ **Daily Routine**: Use a broad-spectrum sunscreen for optimal results and avoid washing skin immediately before application.

Data on File. Independent study, Cyspera Original + versus placebo, 9 volunteers, 12 weeks (Spain, 2024)
Data on File. Independent in use study under gynecological control, Cyspera Original +, 11 women, 4 weeks (Poland, 2024)

BOOST – InflammAging

Cyspera Boost

Isobionic-Amide
(Isobionic-Amide: 5%, Retinol : 0.075%,
0.9% ascorbyl palmitate, 0.9% sodium ascorbyl phosphat

Restore skin affected by inflammaging, revealing a vibrant and resilient complexion.

Claims :

- ✓ **Helps reduce signs of inflammaging and photoaging**
- ✓ **Supports skin barrier function and resilience**
- ✓ **Improves skin radiance, health and overall quality**
- ✓ **Enhances and prolongs results of pigment correction**

Results:

- ✓ **85% reduction of erythema** after 3 days vs. untreated skin[1]
- ✓ **95%** saw **reversed signs of photoaging** after 8 weeks of use[2]
- ✓ **84%** reported **enhanced overall skin health**[2]
- ✓ **86%** noticed a **more radiant and luminous** complexion[2]
- ✓ **95%** experienced a **reduction in wrinkles**[2]

How to Use:

- ✓ **Application:** Use after applying Cyspera Intensive or Original+ to maintain and enhance results.
- ✓ **Routine:** Apply daily during maintenance or as part of a daily routine to lock in glow and hydration.

Protocol options

Cyspera® can be used as a stand alone routine, or can be combined with :

Skin procedure

- ✓ Cyspera® can be applied until skin procedure. After skin procedure, wait for end of redness, desquamation before applying again Cyspera®.
- ✓ Cyspera® can be associated with pigmentary, vascular or ablative lasers, microneedling, Hydrofacial, Derma-abrasion, peelings, etc.

Oral products

- ✓ Cyspera® can be combined with oral tranexamic acid, oral anti-acne, oral antibiotics.
- ✓ Cyspera® can be combined with oral retinoids, only by limiting frequency of application to 5min, 2x/3x weekly.

Injection

- ✓ Cyspera® can be combined with injection, including injection of tranexamic acid, by simply avoiding the application of the product the same day of the injection.

Other topicals

- ✓ Avoid concomitant use of retinoids, AHA, ethanol-based products (such as toner), especially at start of Cyspera. After 4 weeks of use, possible to add retinoids, AHA back in.
- ✓ Cyspera® can generally be combined with Vitamin C and Hyaluronic acid.

How long should the patient use the treatment ?

Until the lesions disappear :

- ✓ Daily use.
- ✓ Final results usually achieved after 3 to 5 months of daily use (no limit for daily use ! No need to stop after 16 weeks !).
- ✓ First visible results usually begin after ~4 weeks of application.

Maintenance phase

- ✓ Twice weekly applications.
- ✓ Needed for melasma, lentigo and photoaged skin.
- ✓ Not needed for post-inflammatory hyperpigmentation (if the initial cause has been resolved).
- ✓ No time limit for the maintenance phase (no long-term side effects).
- ✓ Possible to go back to daily use if necessary.

Can be use during summer-time and suitable for all phototypes.

Management of Sides effects

Transient tingling, warm sensations or mild redness: usually subside in a few minutes.

Irritation may happen in the case of:

- ✓ Prolonged time of application of Cyspera Intensive™ from the beginning.
- ✓ Washed skin just before the application of Cyspera Intensive™.
- ✓ Combination with other potential irritant product (retinoids, ethanol-based products, peeling, AHA,..).
- ✓ Use of a thick layer of the cream.
- ✓ Very dry skin or already irritated skin : moisturizing the skin before the application of the Cyspera Intensive™ prevent this situation.

→ PIH may occur in the case of prolonged non managed skin irritation.
→ In case of irritation, discontinue use until skin recovers, then restart application of Cyspera Intensive™ for 5 minutes or reduce frequency of use (2/3x per week).

BENEFITS & KEY POINTS Efficacy

UV Photoprotection	Strong Antioxidant	Increases NAD+ and cell life span	Increases intracellular glutathione
Reduces melanocyte inflammaging	Textural improvements	Radiance, glowing	Anti-melanogenic
No photosensitivity	Non-carcinogenic, Non-mutagenic	Non-cytotoxic	No thinning of the skin (no corticosteroid)
Safe for all skin types fitz 1-6	No hypopigmentation / hyperpigmentation	No risk of ochronosis	No halo or greying affect on darker skin

Conclusion : Cyspera® Pigment Correction

The first line non-HQ option in hyperpigmentation

Sole **non-hydroquinone** topical regimen clinically proven

- ✓ **as effective as Kligman's formula**,
- ✓ **with same onset of action**

Option for **long-term maintenance therapy** for melasma, thanks to an **absence of long-term side effects** and a **high patient's satisfaction.**